News headlines about Evolent Health (NYSE:EVH) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Evolent Health earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 46.690079169587 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Evolent Health (NYSE:EVH) traded up $0.10 during trading hours on Friday, hitting $14.05. The stock had a trading volume of 678,939 shares, compared to its average volume of 1,010,000. The company has a market cap of $1,090.00 and a P/E ratio of -12.32. The company has a current ratio of 3.34, a quick ratio of 3.34 and a debt-to-equity ratio of 0.11. Evolent Health has a 1 year low of $10.30 and a 1 year high of $27.50.
Evolent Health (NYSE:EVH) last released its earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. The firm had revenue of $107.90 million during the quarter, compared to the consensus estimate of $104.49 million. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The company’s revenue was up 79.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.26) EPS. analysts expect that Evolent Health will post -0.57 EPS for the current fiscal year.
A number of research analysts have commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a report on Sunday, December 3rd. SunTrust Banks reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a report on Friday, November 3rd. Goldman Sachs Group lowered Evolent Health from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, November 7th. Leerink Swann set a $25.00 price objective on Evolent Health and gave the company a “buy” rating in a report on Saturday, November 18th. Finally, Citigroup assumed coverage on Evolent Health in a report on Thursday, January 4th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the stock. Evolent Health presently has a consensus rating of “Buy” and a consensus target price of $28.00.
TRADEMARK VIOLATION NOTICE: “Evolent Health (NYSE:EVH) Earns Media Sentiment Score of 0.14” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/02/evolent-health-evh-given-daily-media-sentiment-rating-of-0-14.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.